$0.10
11.62%
Nasdaq, Fri, May 30 2025
ISIN
BMG0360L1000
Symbol
CYTO
Sector
Industry

Altamira Therapeutics Ltd Stock price

$0.10
+0.01 11.00% 1M
-0.33 76.53% 6M
-0.01 9.59% YTD
-1.37 93.20% 1Y
-299.90 99.97% 3Y
-389.38 99.97% 5Y
-34,639.90 100.00% 10Y
Nasdaq, Closing price Fri, May 30 2025
+0.01 11.62%
ISIN
BMG0360L1000
Symbol
CYTO
Sector
Industry

Key metrics

Market capitalization $570.00k
Enterprise Value $930.00k
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.20
EV/Sales (TTM) EV/Sales 15.52
P/S ratio (TTM) P/S ratio 9.52
P/B ratio (TTM) P/B ratio 0.04
Revenue growth (TTM) Revenue growth -80.65%
Revenue (TTM) Revenue $60.00k
EBIT (operating result TTM) EBIT $-740.30k
Free Cash Flow (TTM) Free Cash Flow $4.65m
Cash position $70.00k
EPS (TTM) EPS $-0.13
Short interest 1.35%
Show more

Is Altamira Therapeutics Ltd a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.

Altamira Therapeutics Ltd Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Altamira Therapeutics Ltd:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Altamira Therapeutics Ltd:

Buy
100%

Financial data from Altamira Therapeutics Ltd

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
0.06 0.06
81% 81%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses - -
- Research and Development Expense 1.03 1.03
95% 95%
1,717%
-0.62 -0.62
98% 98%
-1,033%
- Depreciation and Amortization 0.12 0.12
71% 71%
200%
EBIT (Operating Income) EBIT -0.74 -0.74
97% 97%
-1,234%
Net Profit -0.29 -0.29
99% 99%
-483%

In millions USD.

Don't miss a Thing! We will send you all news about Altamira Therapeutics Ltd directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Altamira Therapeutics Ltd Stock News

Neutral
GlobeNewsWire
5 months ago
HAMILTON, BERMUDA, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (OTCQB: CYTOF), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that on December 18, 2024 it received notice that the Nasdaq Hearings Panel (the "Panel") had determined to delist the Company's common shares from...

Company Profile

Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through Switzerland and Australia geographical segments. Its product pipeline includes AM-125, AM-201, AM301, Sonsuvi, and Keyzilen. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.

Head office Bermuda
CEO Thomas Meyer
Founded 2003
Website aurismedical.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today